ByteDance AI drug discovery unit Anew Labs raises $290M at $1.5B valuation
Anew Labs, the AI drug discovery unit ByteDance spun off, closed a $290 million funding round on 16 September 2026 at a valuation of $1.5 billion. The funding came after the company's spin-off.
Who is affected and how
- pharmaceuticals
- A technology giant's spun-off AI unit is entering drug discovery with substantial capital, a matter for partnership planning and competitor monitoring.
Sources
- ByteDance's Anew Labs raises $290M for AI drug discovery at $1.5B valuationdealroom · Sep 16, 2026
- TikTok parent ByteDance raises cash for drug AI spinout Anew - pharmaphorumpharmaphorum.com · Sep 16, 2026 · magyar
- ByteDance AI Drug Unit Anew Labs Raises $290M After Spin-Off, Valued at $1.5B - Emirates 24|7emirates247.com · Sep 16, 2026
- ByteDance's Anew Labs raises $290M for AI drug discovery at $1.5B valuation - Dealroomapp.dealroom.co · Sep 16, 2026
- ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boomsouth china morning post · Sep 18, 2026
- China's AI Drug Discovery Startup Anew Labs Raises $290M at $1.5B Valuationindexbox · Sep 18, 2026
- ByteDance spin-off Anew Labs raises US$290m for AI drug discovery models - MedPath Trialtrial.medpath.com · Sep 18, 2026
- ByteDance completes $290 million fundraising for AI drug unit after its spin-off, sources sayreuters · Sep 16, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.